← back to search

Noah Federman

Dana-Farber Cancer Institute · US
Area of research
Pulmonary and Respiratory Medicine · Rheumatology
Research interest
Research interests include Sarcoma Diagnosis and Treatment, Lung Cancer Treatments and Mutations, Bone Tumor Diagnosis and Treatments, and Neuroblastoma Research and Treatments.
h-index
39
citations
8,966
works
232
NIH funding
primary concept
Medicine
email

Recent publications

Exposure to Acetaminophen (Paracetamol) during Pregnancy and Childhood Cancer: A Population-Based Cohort Study in Taiwan.
2026cited by 1position: contributordoi
Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors
Journal of Clinical Oncology 2025cited by 12position: middledoi
Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial
Journal of Clinical Oncology 2025cited by 7position: middledoi
Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistance
Signal Transduction and Targeted Therapy 2025cited by 2position: middledoi
2730P Efficacy of nirogacestat in patients with desmoid tumors and presence or absence of poor prognostic factors: Post hoc analyses of the phase III DeFi trial
Annals of Oncology 2025cited by 0position: middledoi
The landscape of drug sensitivity and resistance in sarcoma
Cell stem cell 2024cited by 55position: middledoi
Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma
Journal of Clinical Oncology 2024cited by 33position: middledoi
Efficacy and safety of nirogacestat in patients with desmoid tumor and <i>adenomatous polyposis coli</i><i> (APC)</i> mutation: Phase 3 DeFi analyses.
Journal of Clinical Oncology 2024cited by 5position: middledoi
Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors
New England Journal of Medicine 2023cited by 233position: middledoi
Adolescent and Young Adult (AYA) Oncology, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network 2023cited by 126position: middledoi
Fibroblast Activation Protein Expression in Sarcomas
Sarcoma 2023cited by 38position: lastdoi
SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma
Cancers 2023cited by 37position: lastdoi
Maternal anemia and the risk of childhood cancer: A population-based cohort study in Taiwan.
2023cited by 8position: contributordoi
Maternal migraine and risk of pediatric cancers.
2023cited by 6position: contributordoi
A pilot study evaluating the use of sirolimus in children and young adults with desmoid-type fibromatosis.
2023cited by 4position: contributordoi
Personalized chordoma organoids for drug discovery studies
Science Advances 2022cited by 71position: middledoi
Coupling Lipid Labeling and Click Chemistry Enables Isolation of Extracellular Vesicles for Noninvasive Detection of Oncogenic Gene Alterations
Advanced Science 2022cited by 45position: middledoi
Molecular pathogenesis of desmoid tumor and the role of γ-secretase inhibition.
2022cited by 31position: contributordoi
REsCue trial: Randomized controlled clinical trial with extended-release calcifediol in symptomatic COVID-19 outpatients
Nutrition 2022cited by 23position: middledoi
Efficacy and safety of larotrectinib in pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive cancer: An expanded dataset.
Journal of Clinical Oncology 2022cited by 12position: middledoi
A phase 1 dose-escalation/expansion clinical trial of mocetinostat in combination with vinorelbine in adolescents and young adults with refractory and/or recurrent rhabdomyosarcoma: Interim results.
Journal of Clinical Oncology 2022cited by 11position: firstdoi
463P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer with an extended follow-up
Annals of Oncology 2022cited by 1position: middledoi
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
The Lancet Oncology 2020cited by 985position: middledoi
Coupling Nanostructured Microchips with Covalent Chemistry Enables Purification of Sarcoma‐Derived Extracellular Vesicles for Downstream Functional Studies
Advanced Functional Materials 2020cited by 39position: middledoi
Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung
Sarcoma 2020cited by 27position: middledoi
Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung.
2020cited by 21position: contributordoi
1955P Survival benefits of larotrectinib in an integrated dataset of patients with TRK fusion cancer
Annals of Oncology 2020cited by 17position: middledoi
Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer
Expert Review of Clinical Pharmacology 2019cited by 75position: firstdoi
A Mobile-Based Mindfulness and Social Support Program for Adolescents and Young Adults With Sarcoma: Development and Pilot Testing.
2019cited by 31position: contributordoi
Pathologic Response to Neoadjuvant Therapy is Associated With Improved Long-term Survival in High-risk Primary Localized Malignant Peripheral Nerve Sheath Tumors
American Journal of Clinical Oncology 2019cited by 30position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Leo Mascarenhas · Cedars-Sinai Medical Center14 papers (2013–2025)Theodore W. Laetsch · Children's Hospital of Philadelphia10 papers (2017–2025)Catherine M. Albert · University of Washington10 papers (2017–2022)Birgit Geoerger · Institut Gustave Roussy9 papers (2017–2025)Scott D. Nelson · Vanderbilt University Medical Center9 papers (2012–2023)Arun S. Singh · University of Santa Monica8 papers (2014–2022)Fritz C. Eilber · APLA Health8 papers (2012–2023)Brian Turpin · Cincinnati Children's Hospital Medical Center7 papers (2013–2020)Ramamoorthy Nagasubramanian · Nemours Children's Clinic7 papers (2017–2025)Alberto S. Pappo · University of Tennessee Health Science Center7 papers (2017–2025)François Doz · Institut Curie7 papers (2017–2022) · 7 papers (2019–2026)Steven G. DuBois · Harvard University7 papers (2017–2025)Nicholas M. Bernthal · University of California, Los Angeles7 papers (2012–2022)Stefan Bielack · University of Cincinnati Medical Center6 papers (2017–2025)Sheri L. Spunt · Stanford University6 papers (2013–2020)Cornelis M. van Tilburg · Friedrich Schiller University Jena6 papers (2017–2025)Sarah Dry · University of California, Los Angeles5 papers (2016–2023)Jane Yanagawa · University of California, Los Angeles5 papers (2014–2022)Ray McDermott · University College Dublin4 papers (2018–2022)